StreetInsider.com News Articles

NeuroOne joins Dartmouth on $1M NIH neurotransmitter sensing grant

Thu, 08 Oct 2026 16:01:56 -0400

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has entered into a research and development subaward agreement with Dartmouth College to support the development of neurotransmitter sensing technology, according to a company statement.

Dartmouth researchers, led by Associate Professor of Engineering Hui Fang, received a National Institutes of Health grant of approximately $1 million for the first year, with additional funding expected over the following two years. The grant, titled "Translating Novel Carbon Coating Towards Integrated Sub-Second Neurotransmitter Sensors in Humans," is funded by the National Institute of Neurological Disorders and Stroke through the NIH BRAIN Initiative.

NeuroOne will receive approximately $200,000 through April

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

Thu, 08 Oct 2026 16:01:00 -0400

New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027

EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology.

Researchers at Dartmouth College, led by Associate Professor of Engineering Hui Fang, have received a National Institutes of Health (NIH) grant of approximately $1

NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology

Thu, 08 Oct 2026 16:01:00 -0400

New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027

Researchers at Dartmouth College, led by Associate Professor of Engineering Hui Fang, have received a National Institutes of Health (NIH) grant of approximately $1

Form 8-K NEUROONE MEDICAL TECHNOL For: Oct 05

Mon, 05 Oct 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20261005/27146759.html

NeuroOne reports 38% Q4 revenue growth, lands $4.5M purchase order

Mon, 05 Oct 2026 09:17:16 -0400

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported preliminary fourth-quarter fiscal 2026 product revenue of approximately $3.8 million, a 38.4% increase compared to approximately $2.7 million in the same period a year earlier, according to a company statement.

For the full fiscal year ended September 30, 2026, NeuroOne expects product revenue of approximately $10.5 million, representing 15.6% year-over-year growth and reaching the top of its previously issued guidance range of $9.2 million to $10.5 million.

In September 2026, the company secured a $4.5 million purchase order, which it described as the largest in its history. Approximately $1.0 million of that order shipped in

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

Mon, 05 Oct 2026 09:17:00 -0400

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million

Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

NeuroOne expects to report fourth quarter

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

Mon, 05 Oct 2026 09:17:00 -0400

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million

Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

NeuroOne expects to report fourth quarter

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

Thu, 17 Sep 2026 09:05:00 -0400

Agreement Covers Key Southern California Counties Including Los Angeles Metro as NeuroOne Broadens Commercial Access in Key U.S. Markets

EDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal Nerve Ablation System. The agreement covers key counties, including the Los Angeles metropolitan area, expanding commercial access in an important U.S. market and advancing the Company’s strategy to build distribution across key

NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement

Thu, 17 Sep 2026 09:05:00 -0400

Agreement Covers Key Southern California Counties Including Los Angeles Metro as NeuroOne Broadens Commercial Access in Key U.S. Markets

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Johns Emily J.

Fri, 28 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260828/26999195.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Johns Emily J.

Fri, 28 Aug 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260828/26999195.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Volker Christopher

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998958.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Volker Christopher

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998958.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Christianson Mark

Fri, 28 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26998900.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Christianson Mark

Fri, 28 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260828/26998900.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Mertens Steve

Fri, 28 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260828/26998840.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Mertens Steve

Fri, 28 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260828/26998840.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Rosa David A

Fri, 28 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260828/26998793.html

Form 4 NEUROONE MEDICAL TECHNOL For: Aug 28 Filed by: Rosa David A

Fri, 28 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260828/26998793.html

Form 8-K NEUROONE MEDICAL TECHNOL For: Aug 27

Thu, 27 Aug 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260827/26985990.html

Form 8-K NEUROONE MEDICAL TECHNOL For: Aug 27

Thu, 27 Aug 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20260827/26985990.html

Neuroone Medical Technologies (NMTC) PT Lowered to $5 at Maxim Group

Fri, 14 Aug 2026 08:32:24 -0400

Maxim Group analyst Anthony Vendetti lowered the price target on Neuroone Medical Technologies (NASDAQ: NMTC) to $5.00 (from $13.00) while maintaining a Buy rating.

Form 10-Q NEUROONE MEDICAL TECHNOL For: Jun 30

Thu, 13 Aug 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26917002.html

Form 10-Q NEUROONE MEDICAL TECHNOL For: Jun 30

Thu, 13 Aug 2026 08:21:00 -0400

si-local-file:///var/storage/secattach/20260813/26917002.html

Form 8-K NEUROONE MEDICAL TECHNOL For: Aug 13

Thu, 13 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916972.html